HighTower Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

HighTower Advisors’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,000	Closed	-$48K	–	3739
2021 Q4	$48K	Hold	15,000	–	–	﹤0.01%	3028
2021 Q3	$53K	Sell	15,000 -115	-0.8%	-$384	﹤0.01%	2933
2021 Q2	$48K	Buy	15,115 +115	+0.8%	+$362	﹤0.01%	2898
2021 Q1	$51K	Buy	15,000 +5,000	+50%	+$15.6K	﹤0.01%	2831
2020 Q4	$25K	Hold	10,000	–	–	﹤0.01%	2464
2020 Q3	$21K	Buy	+10,000	New	+$23.8K	﹤0.01%	2370

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCA

VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

HighTower Advisors's ENZ Position: Q1 2022 in Review

HighTower Advisors sold out of Enzo Biochem, Inc. (ENZ) in Q1 2022, closing a stake of 15,000 shares — an estimated $48K sold.

HighTower Advisors first reported a position in ENZ in Q3 2020 and held it in 6 quarters. The position peaked at $53K in Q3 2021. 51 funds tracked by Wall St. Rank hold ENZ as of Q1 2022.

HighTower Advisors reported no remaining Enzo Biochem, Inc. position as of Q1 2022 after selling out during the quarter.
HighTower Advisors sold 15,000 Enzo Biochem, Inc. shares in Q1 2022, an estimated $48K.
HighTower Advisors first reported a position in Enzo Biochem, Inc. in Q3 2020 and held it in 6 quarters.
HighTower Advisors's Enzo Biochem, Inc. position peaked at $53K in Q3 2021.
51 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2022.

Based on HighTower Advisors's 13F filing for Q1 2022, filed 12 May 2022.